XyloCor Therapeutics Secures $67.5 Million in Series B Funding to Advance Cardiovascular Gene Therapy

Funding:
XyloCor Therapeutics has raised $67.5 million in Series B financing to support the clinical development of its novel gene therapy for cardiovascular disease134.

Clinical Trials: The funding will be used for two Phase 2 trials:
EXACT-2, a randomized, double-blind trial for refractory angina using a new non-surgical method of endocardial administration, and a second trial as an adjunctive treatment to coronary artery bypass graft surgery (CABG)13.

Lead Investor:
Jeito Capital led the Series B funding round, with existing investors EQT, Fountain Healthcare Partners, and Lumira Ventures also participating. Rachel Mears from Jeito Capital will join XyloCor's Board of Directors13.

Therapeutic Approach:
XC001 (encoberminogene rezmadenovec) offers a new therapeutic approach for debilitating and chronic conditions affecting over one million people in the United States who have no treatment options13.

Previous Results:
Positive results from the Phase 1/2 clinical trial (EXACT) demonstrated the disease-modifying potential of XC001 to relieve chest pain in patients with refractory angina by reducing ischemic burden3.

Sources:

1. https://pulse2.com/xylocor-therapeutics-67-5-million-series-b-raised-for-advancing-clinical-development-of-gene-therapy-in-cardiovascular-disease/

3. http://www.xylocor.com/news.html

4. https://www.longwoodfund.com/2025/01/07/xylocor-therapeutics-raises-67-5-million-in-series-b-financing-to-advance-clinical-development-of-novel-gene-therapy-in-cardiovascular-disease/